Remmo
Generic Name
Remogliflozin Etabonate
Manufacturer
Square Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| remmo 40 mg tablet | ৳ 14.00 | ৳ 210.00 |
Description
Overview of the medicine
Remmo 40 mg Tablet contains Remogliflozin Etabonate, which is an oral antidiabetic drug used for the treatment of type 2 diabetes mellitus.
Uses & Indications
Dosage
Adults
The usual starting dose of Remogliflozin Etabonate is 100 mg twice daily or 200 mg once daily. For the 40 mg tablet, specific dosing instructions must be followed as advised by a physician.
Elderly
No dosage adjustment is generally required based on age; however, renal function should be assessed before initiating and periodically during treatment.
Renal_impairment
Not recommended for patients with an eGFR less than 30 mL/min/1.73m². Dosage adjustment may be required for eGFR 30-60 mL/min/1.73m².
How to Take
Take orally, with or without food, typically in the morning. Swallow the tablet whole with water.
Mechanism of Action
Remogliflozin Etabonate selectively inhibits Sodium-Glucose Co-transporter 2 (SGLT2) in the renal tubules, reducing glucose reabsorption and increasing urinary glucose excretion, thereby lowering blood glucose levels.
Pharmacokinetics
Onset
Within a few hours of administration.
Excretion
Mainly excreted as metabolites, approximately 80% via urine and 20% via feces.
Half life
Approximately 2-4 hours.
Absorption
Rapidly absorbed after oral administration. Peak plasma concentrations are reached within 0.5-2 hours.
Metabolism
Extensively metabolized, primarily via glucuronidation.
Side Effects
Contraindications
- Hypersensitivity to Remogliflozin Etabonate or any component of the formulation.
- Severe renal impairment (eGFR < 30 mL/min/1.73m²), end-stage renal disease, or patients on dialysis.
- Diabetic ketoacidosis (DKA).
Drug Interactions
Diuretics
May increase the risk of dehydration and hypotension.
Rifampicin
May decrease the efficacy of Remogliflozin by inducing its metabolism.
Insulin and Insulin Secretagogues (e.g., sulfonylureas)
May increase the risk of hypoglycemia. A lower dose of insulin or sulfonylurea may be required.
Storage
Store below 30°C. Protect from light and moisture. Keep out of reach of children.
Overdose
In the event of an overdose, symptomatic treatment and supportive care should be initiated. Gastric lavage may be considered if ingestion is recent.
Pregnancy & Lactation
Not recommended during pregnancy, especially during the second and third trimesters, due to potential adverse effects on fetal renal development. It is unknown if Remogliflozin is excreted in human milk; therefore, it is not recommended during breastfeeding.
Side Effects
Contraindications
- Hypersensitivity to Remogliflozin Etabonate or any component of the formulation.
- Severe renal impairment (eGFR < 30 mL/min/1.73m²), end-stage renal disease, or patients on dialysis.
- Diabetic ketoacidosis (DKA).
Drug Interactions
Diuretics
May increase the risk of dehydration and hypotension.
Rifampicin
May decrease the efficacy of Remogliflozin by inducing its metabolism.
Insulin and Insulin Secretagogues (e.g., sulfonylureas)
May increase the risk of hypoglycemia. A lower dose of insulin or sulfonylurea may be required.
Storage
Store below 30°C. Protect from light and moisture. Keep out of reach of children.
Overdose
In the event of an overdose, symptomatic treatment and supportive care should be initiated. Gastric lavage may be considered if ingestion is recent.
Pregnancy & Lactation
Not recommended during pregnancy, especially during the second and third trimesters, due to potential adverse effects on fetal renal development. It is unknown if Remogliflozin is excreted in human milk; therefore, it is not recommended during breastfeeding.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
24 to 36 months from manufacturing date
Availability
Pharmacies, hospitals
Approval Status
Approved (e.g., by DGDA)
Patent Status
Patented (Innovator), Generics Available
Clinical Trials
Remogliflozin Etabonate has undergone clinical trials to assess its efficacy and safety in patients with type 2 diabetes, including studies on its cardiovascular and renal outcomes.
Lab Monitoring
- Renal function (eGFR) before initiation and periodically thereafter.
- Blood glucose and HbA1c levels regularly.
- Lipid profile and electrolytes as needed.
Doctor Notes
- Monitor eGFR regularly, especially in elderly patients or those with pre-existing renal impairment.
- Educate patients on the symptoms of DKA and genital infections, and advise seeking immediate medical attention if they occur.
- Emphasize the importance of adequate hydration to minimize the risk of volume depletion.
Patient Guidelines
- Maintain adequate hydration.
- Monitor for symptoms of urinary tract infections or genital mycotic infections.
- Be aware of the signs and symptoms of diabetic ketoacidosis (e.g., nausea, vomiting, abdominal pain, rapid breathing).
Missed Dose Advice
If you miss a dose, take it as soon as you remember, unless it is almost time for your next dose. Do not take a double dose to make up for a missed one.
Driving Precautions
Remogliflozin Etabonate may cause dizziness in some patients. Patients should exercise caution when driving or operating machinery until they know how the medication affects them.
Lifestyle Advice
- Follow a balanced diet as recommended by your healthcare provider.
- Engage in regular physical activity.
- Stay well-hydrated, especially in hot weather or during illness.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.
Other Medicines in Remmo Brand
Other medicines available under the same brand name
